Effects of Isoflavone Supplementation on the Response to Medroxyprogesterone in Premenopausal Women with Nonatypical Endometrial Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled Trial
Table 1
General characteristics of study participants.
Placebo group (n = 45)
Isoflavone group (n = 43)
Age (y)
37.2 ± 4.2
37.7 ± 4.1
0.59
Height (m)
158.7 ± 9.0
161.0 ± 9.9
0.24
Weight at the study baseline (kg)
75.4 ± 10.1
77.7 ± 9.2
0.27
Weight at the end of the trial (kg)
75.7 ± 10.2
77.9 ± 9.6
0.29
BMI at the study baseline (kg/m2)
30.1 ± 4.7
30.2 ± 4.3
0.96
BMI at the end of the trial (kg/m2)
30.2 ± 4.8
30.3 ± 4.3
0.99
SBP (mmHg)
124.3 ± 10.9
122.2 ± 10.0
0.34
DBP (mmHg)
75.5 ± 7.2
75.7 ± 5.3
0.91
Diabetes mellitus
5 (11.1%)
6 (14%)
0.68
BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure. Data are presented as a mean ± SD or numbers (%). aObtained from the independent samples t-test. Obtained from the chi-square test.
